United States of America
Andrew Schiff, M.D., has served as a member of Aclaris Therapeutics’ board of directors since August 2017. Dr. Schiff joined Aisling Capital in September 1999 and has served as a Managing Partner since 2006. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff served as a Director of ZELTIQ Aesthetics, Inc., a publicly held medical technology company, from 2010 until its acquisition by Allergan plc in May 2017. He also served on the board of directors of Agile Therapeutics, Inc., a publicly held women's health specialty pharmaceutical company, from 2012 until February 2016. Dr. Schiff currently serves as a Director of a number of private companies. He is a longtime supporter and board member of the Visiting Nurse Service of New York, as well as other charitable organizations. Dr. Schiff received his Doctor of Medicine from Cornell University Medical College, his Master of Business Administration from Columbia University, and his Bachelor of Science with honors in Neuroscience from Brown University.
Host defense mechanisms,LPS effects on neurotransmitters